MediWound Ltd. (MDWD) shares are down 28 percent on Tuesday morning trade after U.S. Food and Drug Administration said it determined that the biologics license application or BLA for NexoBrid cannot be approved in the present form.
In the complete response letter, FDA said it has identified issues related to the Chemistry, Manufacturing, and Controls or CMC section of the BLA and requested additional CMC information. The FDA also wants to inspect NexoBrid's manufacturing facilities in Israel and Taiwan prior to BLA approval.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.